[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652101":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":43,"responsibleParty":65,"collaborators":37,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":37,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":37,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":37,"overallStatus":46,"whyStopped":37,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Beni-Suef University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A (Nebulized dexmedetomidine ):","ACTIVE_COMPARATOR","About 73 cases suffering from Chronic Migraine will undergo Nebulized dexmedetomidine (1 mcg\u002Fkg in 4 mL normal saline) Administered via jet nebulizer for 3 sessions per week for 2weeks",[13],"Drug: Dexmedetomidine",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B (Placebo):","PLACEBO_COMPARATOR","About 73 cases suffering from Chronic Migraine will undergo Nebulized 4 mL normal saline Administered via jet nebulizer for 3 sessions per week for 2weeks",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dexmedetomidine","Assessment the effect of nebulized dexmedetomidine on central Sensitization and Chronification in patients with episodic or early chronic migraine by using CGRP serum levels and trigeminal neurophysiological biomarkers (nociceptive blink reflex (nBR) and trigeminal somatosensory evoked potentials (TSSEP)).",[9,15],[26],"CGRP serum levels and trigeminal neurophysiological biomarkers",[28],{"name":29,"affiliation":30,"role":31},"Hatem ElMoutaz Mahmoud, M.D","Professor of Anesthesiology, Surgical Intensive Care and Pain Management,Faculty of Medicine","STUDY_CHAIR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Ibthal Osama Fathy Ibrahim, MSc","CONTACT","+201098273360",null,"Ibthal21@gmail.com",{"name":40,"role":35,"phone":41,"phoneExt":37,"email":42},"Wael Fathy Hassan, Professor","+201006527133","drwaelfathy@med.bsu.edu.eg",[44],{"facility":45,"status":46,"city":47,"state":37,"zip":37,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Beni-Suef University Hospital","RECRUITING","Banī Suwayf","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],31.09785,29.07441,{"lat":54,"lon":53},[57,61],{"name":58,"role":35,"phone":59,"phoneExt":37,"email":60},"Dina Mahmoud Fakhry, Lecturer","+201289998680","Drdina.mahmoud@med.bsu.edu.eg",{"name":62,"role":35,"phone":63,"phoneExt":37,"email":64},"Reem Mohammed Sabry, Lecturer","+201122160532","Doctor_neurophysiology@med.bsu.edu.eg",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"PRINCIPAL_INVESTIGATOR","Ibthal Osama Fathy Ibrahim","Assistant lecturer at Anesthesiology, surgical intensive care, and pain managemen Departmentt","100652101","effect-of-nebulized-dexmedetomidine-on-central-sensitization-and-chronification-in-migraine-100652101",false,"NCT07769255","Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine","Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine: A Randomized Controlled Trial Using Calcitonin Gene Related Peptide and Trigeminal Neurophysiological Biomarkers","Inclusion Criteria:\n\n* Diagnosis of Early chronic migraine (\\\u003C6 months of ≥15 headache days\u002Fmonth), per ICHD-3 criteria.\n* No preventive migraine therapy in the prior 8 weeks.\n\nExclusion Criteria:\n\n* Presence of cardiopulmonary, psychiatric, or neurological comorbidities.\n* Current use of sedatives, opioids, or CGRP-targeting therapies.\n* Pregnancy or breastfeeding.","ALL","18 Years","55 Years",{"count":80,"type":81},146,"ESTIMATED","INTERVENTIONAL",[84],"NA","Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems.\n\nDexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .",[87],"Chronic Migraine","2026-08-12",{"date":90,"type":91},"2026-08-17","ACTUAL",{"date":93,"type":81},"2026-09-01",{"date":95,"type":81},"2027-03-10",{"name":5,"class":6},1]